Poolbeg Pharma (LON:POLB) Stock Price Down 0.5% – What’s Next?

Shares of Poolbeg Pharma PLC (LON:POLB) fell 0.5% on Thursday . The company traded as low as GBX 4 and last traded at GBX 4.08. 265,187 shares traded hands during trading, a decline of 81% from the average session volume of 1,414,012 shares. The stock had previously closed at GBX 4.10.

Analysts Set New Price Targets

Separately, Shore Capital Group reiterated a “house stock” rating on shares of Poolbeg Pharma in a report on Wednesday, January 28th.

Poolbeg Pharma Stock Down 0.5%

The company’s 50 day simple moving average is GBX 4.46 and its two-hundred day simple moving average is GBX 4.01. The company has a market capitalization of £28.75 million, a price-to-earnings ratio of -3.58 and a beta of 2.00.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.